Sergio Giralt focuses on Internal medicine, Transplantation, Surgery, Hematopoietic stem cell transplantation and Gastroenterology. Internal medicine and Oncology are frequently intertwined in his study. He has included themes like Survival rate, Regimen and Immunology in his Transplantation study.
His Surgery study frequently draws connections between related disciplines such as Transplantation Conditioning. His Hematopoietic stem cell transplantation research focuses on Cancer and how it connects with Cohort. The various areas that Sergio Giralt examines in his Gastroenterology study include Tacrolimus, Cumulative incidence, Complication, Immunopathology and Hodgkin's lymphoma.
The scientist’s investigation covers issues in Internal medicine, Transplantation, Surgery, Oncology and Hematopoietic stem cell transplantation. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. In his work, Myeloid is strongly intertwined with Leukemia, which is a subfield of Transplantation.
Surgery is closely attributed to Bone marrow in his research. The study incorporates disciplines such as CD34, Myeloid leukemia, Disease and Toxicity in addition to Oncology. The Hematopoietic stem cell transplantation study combines topics in areas such as Cancer, Survival rate, Hematology, Myelodysplastic syndromes and Transplantation Conditioning.
Sergio Giralt spends much of his time researching Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Multiple myeloma. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, CD34 and Ex vivo. His study in Gastroenterology is interdisciplinary in nature, drawing from both Incidence and Acute leukemia.
His studies in Transplantation integrate themes in fields like Hematopoietic cell, Stem cell and Immunology, Lymphoma. His work carried out in the field of Oncology brings together such families of science as Older patients, Cancer, Myeloid leukemia and Disease. The Hematopoietic stem cell transplantation study combines topics in areas such as Salvage therapy and Retrospective cohort study.
His primary scientific interests are in Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Multiple myeloma. Sergio Giralt has researched Internal medicine in several fields, including Gastroenterology, Ex vivo and CD34. His studies deal with areas such as Hematopoietic cell, Incidence, Hazard ratio, Confidence interval and Stem cell as well as Transplantation.
His Oncology study integrates concerns from other disciplines, such as Adverse effect, Myeloid leukemia and T cell, Immune system. Sergio Giralt combines subjects such as Randomized controlled trial, Fludarabine, Graft-versus-host disease and Cohort with his study of Hematopoietic stem cell transplantation. His Toxicity study combines topics from a wide range of disciplines, such as Surgery and Cytokine release syndrome.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido.
Science Translational Medicine (2014)
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley.
British Journal of Haematology (1998)
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
R H Collins;O Shpilberg;W R Drobyski;D L Porter.
Journal of Clinical Oncology (1997)
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
I F Khouri;M Keating;M Körbling;D Przepiorka.
Journal of Clinical Oncology (1998)
Defining the intensity of conditioning regimens: working definitions.
Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt.
Biology of Blood and Marrow Transplantation (2009)
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd.
The New England Journal of Medicine (2012)
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang.
Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts
M Korbling;D Przepiorka;YO Huh;H Engel.
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Sergio Giralt;Karen Ballen;Douglas Rizzo;Andreas Bacigalupo.
Biology of Blood and Marrow Transplantation (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: